Omead Ostadan Sells 3,540 Shares of Illumina, Inc. (ILMN) Stock
Illumina, Inc. (NASDAQ:ILMN) EVP Omead Ostadan sold 3,540 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $226.91, for a total transaction of $803,261.40. Following the completion of the sale, the executive vice president now owns 26,827 shares of the company’s stock, valued at approximately $6,087,314.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded down $2.39 during trading hours on Tuesday, reaching $211.06. 1,050,098 shares of the company’s stock were exchanged, compared to its average volume of 958,333. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The company has a market capitalization of $32,885.04, a price-to-earnings ratio of 65.86, a PEG ratio of 3.72 and a beta of 0.79. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $230.72.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the business earned $0.97 earnings per share. sell-side analysts expect that Illumina, Inc. will post 3.75 EPS for the current year.
ILMN has been the subject of several analyst reports. Deutsche Bank upgraded shares of Illumina from a “hold” rating to a “buy” rating and lowered their target price for the company from $195.00 to $160.00 in a report on Monday, October 23rd. Canaccord Genuity reiterated a “buy” rating and issued a $230.00 target price (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. Vetr upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target for the company in a research report on Wednesday, August 9th. Argus increased their price target on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Finally, Bank of America increased their price target on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $201.98.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.